Ortiz B, Vázquez C, Martínez C, Giménez J, Sanmartín O, de los Dolores V, Ortega F, Maíquez J, Fliquete MV. [S100 protein as tumoral marker in melanoma patients. Comparative study with sentinel node biopsy and whole body FDG-PET].
Rev Esp Med Nucl 2003;
22:87-96. [PMID:
12646097 DOI:
10.1016/s0212-6982(03)72151-x]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
PURPOSE
Analyze the significance of serum S100 as tumor marker and study it in the sentinel node biopsy and in the whole body FDG-PET studies.
MATERIAL AND METHODS
332 melanoma patients diagnosed of cutaneous melanoma were included (41 untreated and 291 previously treated). Serum levels were measured by an immunoradiometric assay. Cut-off value was 0.2 microg/l.
RESULTS
In the 41 untreated patients, the S100 mean values were: mean 0.36 microg/l, median 0.29 microg/l, with 56.1% of positivities. Serum mean values in stage III and IV were significantly higher than stage I and II (0.489 microg/l vs 0.209 microg/l) (p < 0.05). The mean serum value of S100 in treated patients and without evidence of disease was 0.14 microg/l and the median 0.13 microg/l. Sensitivity and specificity for detection of recurrence or metastases in the follow-up were 76.2% and 88.6%, respectively. There is a correlation of 91.3% between S100 and FDG-PET studies (23 patients). S100 does not provide information on the sentinel lymph node biopsy.
CONCLUSIONS
S100 is not useful to diagnose melanoma in its early stages but it is a good tumor marker for the follow-up and monitoring of melanoma patients.
Collapse